Sale

Hepatitis B Vaccine Market

Hepatitis B Vaccine Market Size, Trends, Analysis, Report: By Type: Single Antigen, Combination; By Age: Pediatrics, Adults; By End User: Hospitals, Clinics, Vaccination Centres; Others; Regional Analysis; Clinical Trials Analysis; Funding and Investment Analysis; Partnership and Collaborations Analysis; Supplier Landscape; 2024-2032

Hepatitis B Vaccine Market Outlook

The hepatitis B vaccine market size in the 7 major markets was valued at USD 4.8 billion in 2023, driven by the increasing incidence of hepatitis B cases across the major markets. The market is expected to grow at a CAGR of 4.8% during the forecast period of 2024-2032, with the values likely to rise from USD 5 billion in 2024 to USD 7.3 billion by 2032.

 

Hepatitis B Vaccine: Introduction

Hepatitis B is a liver infection caused by the hepatitis B virus. The infection may be long term (chronic) or short term (acute). Chronic hepatitis B can put people at the risk of death from cirrhosis and liver cancer. It can spread through fluid transfusion from an infected person and even transfer from a mother to the child. Hepatitis B vaccinations play a crucial role in minimizing the risk of this fatal disease. The vaccinations can protect against the infection for at least 20 years.

 

Hepatitis B Vaccine Market Analysis

With notable advancements within the range vaccines available, the hepatitis B vaccine market value has risen significantly in the recent years. Some of the notable authorized hepatis B vaccinations include Engerix-B, a noninfectious recombinant DNA vaccine, Heplisav-B®, Recombivax HB, and Twinrix hepatitis vaccine, which is indicated for both hepatitis A and B, adding versatility to the market.

 

The hepatitis B vaccine market growth is likely to expediate with the on-going investigations. The U.S. CDC's initiative for Universal Hepatitis B Vaccination in Adults aged 19–59 signals a broader adoption trend. VTP-300, the hepatits B vaccination by Vaccitech is undergoing trials and has shown positive outcomes, indicating its breakthrough in upcoming years.


 
GSK plc's upcoming presentation at The Liver Meeting® 2023 is set to unveil insights from the B-Together phase IIb trial on bepirovirsen. It is an antisense oligonucleotide for chronic hepatitis B showcasing encouraging outcomes, especially in combination with pegylated interferon alfa. The trial evaluates the sequential regimen's efficacy in treating CHB infection, reducing hepatitis B surface antigen, and lowering virus DNA in the blood. Such developments hold a promising future for the vaccinations market in the forecast period.

 

Hepatitis B Vaccine Market Segmentation

Market Breakup by Type

  • Single Antigen
  • Combination

 

Market Breakup by Age

  • Pediatrics
  • Adults

 

Market Breakup by End User

  • Hospitals
  • Clinics
  • Vaccination Centres
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Hepatitis B Vaccine Market Overview

The World Health Organization estimates that the world population may suffer with 1.5 million new hepatitis B infections every year, as a result, the hepatitis B vaccine market demand has increased significantly. North America, particularly the United States, has dominated the market in the historical period. The market share can be accredited to the presence of key market players offering advanced vaccines. The region's well-established healthcare infrastructure and high awareness levels have further propelled market growth.

 

European market has also expanded with its robust healthcare system and proactive vaccination drives. The ongoing research and development activities by pharmaceutical companies, along with collaborations and partnerships among research institutions, continue to drive innovation in the region.

 

Going forward, Asia Pacific and Africa are poised to become pivotal centres for hepatitis B vaccine market share. These regions face a higher burden of hepatitis B infections, demanding high vaccination initiatives. Asia Pacific, being home to densely populated countries with emerging economies, is witnessing a surge in healthcare awareness and infrastructure development. The rising prevalence of hepatitis B in these regions amplifies the urgency for vaccination programs.

 

Hepatitis B Vaccine Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Merck & Co., Inc.
  • Sanofi S.A. 
  • Dynavax Technologies Corporation 
  • GlaxoSmithKline plc. 
  • Pancea Biotech Ltd 
  • Beijing Tiantan Biological Products Co., Ltd. 
  • VBI Vaccines Inc. 
  • Emmy Vaccine Co. Ltd. 
  • Beijing Minhai Biological Technology Co., Ltd.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Age
  • End User
  • Region
Breakup by Type
  • Single Antigen
  • Combination
Breakup by Age
  • Pediatrics
  • Adults
Breakup by End User
  • Hospitals
  • Clinics
  • Vaccination Centres 
  • Others
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Merck & Co.,Inc
  • Sanofi S.A.
  • Dynavax Technologies Corporation
  • GlaxoSmithKline plc.
  • Pancea Biotech Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • VBI Vaccines Inc.
  • Emmy Vaccine Co.,Ltd.
  • Beijing Minhai Biological Technology Co., Ltd.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Hepatitis B Disease Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Hepatitis B Disease Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Hepatitis B Disease Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Hepatitis B Disease Epidemiology Forecast (2017-2032)
        5.3.1    Germany Hepatitis B Disease Epidemiology Forecast (2017-2032)
        5.3.2    France Hepatitis B Disease Epidemiology Forecast (2017-2032)
        5.3.3    Italy Hepatitis B Disease Epidemiology Forecast (2017-2032)
        5.3.4    Spain Hepatitis B Disease Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Hepatitis B Disease Epidemiology Forecast (2017-2032)
    5.4    Japan Hepatitis B Disease Epidemiology Forecast (2017-2032)
6    Hepatitis B Vaccine Market Overview – 7MM
    6.1    Hepatitis B Vaccine Market Historical Value (2017-2023) 
    6.2    Hepatitis B Vaccine Market Forecast Value (2024-2032)
7    Hepatitis B Vaccine Market Landscape – 7MM
    7.1    Hepatitis B Vaccine: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Hepatitis B Vaccine: Product Landscape
        7.2.1    Analysis by Type
        7.2.2    Analysis by Treatment Type
        7.2.3    Analysis by Diagnosis Method
8    Hepatitis B Vaccine Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
    10    Hepatitis B Vaccine Market Dynamics
        10.1    Market Drivers and Constraints
        10.2    SWOT Analysis
        10.3    Porter’s Five Forces Model
        10.4    Key Demand Indicators 
        10.5    Key Price Indicators
        10.6    Industry Events, Initiatives, and Trends  
        10.7    Value Chain Analysis
11    Hepatitis B Vaccine Market Segmentation – 7MM
    11.1    Hepatitis B Vaccine Market by Type
        11.1.1    Market Overview
        11.1.2    Single Antigen
        11.1.3    Combination
    11.2    Hepatitis B Vaccine Market by Age
        11.2.1    Market Overview
        11.2.2    Pediatrics
        11.2.3    Adults
    11.3    Hepatitis B Vaccine Market by End User
        11.3.1    Market Overview
        11.3.2    Hospitals
        11.3.3    Clinics
        11.3.4    Vaccination Centres 
        11.3.5    Others
    11.4    Hepatitis B Vaccine Market by Region
        11.4.1    Market Overview
        11.4.2    United States
        11.4.3    EU-4 and the United Kingdom
            11.4.3.1    Germany
            11.4.3.2    France
            11.4.3.3    Italy
            11.4.3.4    Spain
            11.4.3.5    United Kingdom    
        11.4.4    Japan
12    United States Hepatitis B Vaccine Market
    12.1    Hepatitis B Vaccine Market Historical Value (2017-2023) 
    12.2    Hepatitis B Vaccine Market Forecast Value (2024-2032)
    12.3    Hepatitis B Vaccine Market by Type
    12.4    Hepatitis B Vaccine Market by Treatment Type
13    EU-4 and United Kingdom Hepatitis B Vaccine Market
    13.1    Hepatitis B Vaccine Market Historical Value (2017-2023) 
    13.2    Hepatitis B Vaccine Market Forecast Value (2024-2032)
    13.3    Germany Hepatitis B Vaccine Market Overview
        13.3.1    Hepatitis B Vaccine Market by Type
        13.3.2    Hepatitis B Vaccine Market by Treatment Type
    13.4    France Hepatitis B Vaccine Market Overview
        13.4.1    Hepatitis B Vaccine Market by Type
        13.4.2    Hepatitis B Vaccine Market by Treatment Type
    13.5    Italy Hepatitis B Vaccine Market Overview
        13.5.1    Hepatitis B Vaccine Market by Type
        13.5.2    Hepatitis B Vaccine Market by Treatment Type
    13.6    Spain Hepatitis B Vaccine Market Overview
        13.6.1    Hepatitis B Vaccine Market by Type
        13.6.2    Hepatitis B Vaccine Market by Treatment Type
    13.7    United Kingdom Hepatitis B Vaccine Market Overview
        13.7.1    Hepatitis B Vaccine Market by Type
        13.7.2    Hepatitis B Vaccine Market by Treatment Type
14    Japan Hepatitis B Vaccine Market
    14.1    Hepatitis B Vaccine Market Historical Value (2017-2023) 
    14.2    Hepatitis B Vaccine Market Forecast Value (2024-2032)
    14.3    Hepatitis B Vaccine Market by Type
    14.4    Hepatitis B Vaccine Market by Treatment Type
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    INDIA CDSCO
        15.1.4    JAPAN PMDA
        15.1.5    Others
16    Clinical Trials Analysis
    16.1     Analysis by Trial Registration Year
    16.2    Analysis by Trial Status
    16.3    Analysis by Trial Phase
    16.4    Analysis by Therapeutic Area
    16.5    Analysis by Geography
17    Funding and Investment Analysis
    17.1    Analysis by Funding Instances
    17.2    Analysis by Type of Funding
    17.3    Analysis by Funding Amount
    17.4    Analysis by Leading Players
    17.5    Analysis by Leading Investors
    17.6    Analysis by Geography
18    Partnership and Collaborations Analysis
    18.1    Analysis by Partnership Instances
    18.2    Analysis by Type of Partnership
    18.3    Analysis by Leading Players
    18.4    Analysis by Geography
19    Supplier Landscape
    19.1    Merck & Co.,Inc.
        19.1.1    Financial Analysis
        19.1.2    Product Portfolio
        19.1.3    Demographic Reach and Achievements
        19.1.4    Mergers and Acquisitions
        19.1.5    Certifications
    19.2    Sanofi S.A. 
        19.2.1    Financial Analysis
        19.2.2    Product Portfolio
        19.2.3    Demographic Reach and Achievements
        19.2.4    Mergers and Acquisitions
        19.2.5    Certifications
    19.3    Dynavax Technologies Corporation
        19.3.1    Financial Analysis
        19.3.2    Product Portfolio
        19.3.3    Demographic Reach and Achievements
        19.3.4    Mergers and Acquisitions
        19.3.5    Certifications
    19.4    GlaxoSmithKline plc.
        19.4.1    Financial Analysis
        19.4.2    Product Portfolio
        19.4.3    Demographic Reach and Achievements
        19.4.4    Mergers and Acquisitions
        19.4.5    Certifications
    19.5    Pancea Biotech Ltd
        19.5.1    Financial Analysis
        19.5.2    Product Portfolio
        19.5.3    Demographic Reach and Achievements
        19.5.4    Mergers and Acquisitions
        19.5.5    Certifications
    19.6    Beijing Tiantan Biological Products Co., Ltd.
        19.6.1    Financial Analysis
        19.6.2    Product Portfolio
        19.6.3    Demographic Reach and Achievements
        19.6.4    Mergers and Acquisitions
        19.6.5    Certifications
    19.7    VBI Vaccines Inc.
        19.7.1    Financial Analysis
        19.7.2    Product Portfolio
        19.7.3    Demographic Reach and Achievements
        19.7.4    Mergers and Acquisitions
        19.7.5    Certifications
    19.8    Emmy Vaccine Co.,Ltd.
        19.8.1    Financial Analysis
        19.8.2    Product Portfolio
        19.8.3    Demographic Reach and Achievements
        19.8.4    Mergers and Acquisitions
        19.8.5    Certifications
    19.9    Beijing Minhai Biological Technology Co., Ltd.
        19.9.1    Financial Analysis
        19.9.2    Product Portfolio
        19.9.3    Demographic Reach and Achievements
        19.9.4    Mergers and Acquisitions
        19.9.5    Certifications
20    Hepatitis B Vaccine - Distribution Model (Additional Insight)
    20.1    Overview 
    20.2    Potential Distributors 
    20.3    Key Parameters for Distribution Partner Assessment 
21    Key Opinion Leaders (KOL) Insights (Additional Insight)
22    Company Competitiveness Analysis (Additional Insight)

    22.1    Very Small Companies
    22.2    Small Companies
    22.3    Mid-Sized Companies
    22.4    Large Companies
    22.5    Very Large Companies
23    Payment Methods (Additional Insight)
    23.1    Government Funded
    23.2    Private Insurance
    23.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 4.8 billion in 2023, driven by the increasing prevalence of hepatitis B cases across the7 major markets.

The market is anticipated to grow at a CAGR of 4.8% during the forecast period of 2024-2032, likely to reach a market value of USD 7.3 billion by 2032.

The market demand has increased with the advent of highly efficient vaccinations such as Engerix-B, Heplisav-B®, Recombivax HB, and Twinrix hepatitis vaccine.

The current market trend is marked by the ongoing investigation on vaccines for adults falling the age group of 19-59. One such example is VTP-300 by Vaccitech, which is currently in trials and displayed positive results.

Single antigen and combination are common Hepatitis B vaccine types. 

They are available for pediatrics as well as adults.

Major end users include hospitals, clinics, and vaccination centres. 

The major regions of the market include United States, EU-4 and the United Kingdom, Japan. EU-4 includes Germany, France, Italy, and Spain.

Key players involved in the market are Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc., Pancea Biotech Ltd., Beijing Tiantan Biological Products Co., Ltd., VBI Vaccines Inc., Emmy Vaccine Co. Ltd., Beijing Minhai Biological Technology Co., Ltd., and Dynavax Technologies Corporation.

Purchase Full Report

Mini Report

$ 3499     $1999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 7999     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9999     $5999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER